Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stojanovski

Showing results (291-300 of 296) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 296 results.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2019
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibitionSusan Wyllie, Stephen Brand, Michael Thomas, et al.
ACS Infectious Diseases|October 6, 2016
Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosisYumi Park, Angela Pacitto, Tracy Bayliss, et al.
Journal of Medicinal Chemistry|December 21, 2018
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral LeishmaniasisMichael G Thomas, Manu De Rycker, Myriam Ajakane, et al.
Nature|June 19, 2015
A novel multiple-stage antimalarial agent that inhibits protein synthesisBeatriz Baragaña, Irene Hallyburton, Marcus C S Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 22, 2019
Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosisBeatriz Baragaña, Barbara Forte, Ryan Choi, et al.
Nature|July 27, 2022
Dairying, diseases and the evolution of lactase persistence in EuropeRichard P Evershed, George Davey Smith, Mélanie Roffet-Salque, et al.
Pageof 30

Showing results (291-300 of 296) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 296 results.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2019
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibitionSusan Wyllie, Stephen Brand, Michael Thomas, et al.
ACS Infectious Diseases|October 6, 2016
Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosisYumi Park, Angela Pacitto, Tracy Bayliss, et al.
Journal of Medicinal Chemistry|December 21, 2018
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral LeishmaniasisMichael G Thomas, Manu De Rycker, Myriam Ajakane, et al.
Nature|June 19, 2015
A novel multiple-stage antimalarial agent that inhibits protein synthesisBeatriz Baragaña, Irene Hallyburton, Marcus C S Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 22, 2019
Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosisBeatriz Baragaña, Barbara Forte, Ryan Choi, et al.
Nature|July 27, 2022
Dairying, diseases and the evolution of lactase persistence in EuropeRichard P Evershed, George Davey Smith, Mélanie Roffet-Salque, et al.
Pageof 30